Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

-Advances Reported in All Three Clinical Programs, Including Launch of Key

Bavituximab Phase II Cancer Program-

TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the third quarter of fiscal year (FY) 2008 ended January 31, 2008. The company reported a consolidated net loss of $6,154,000, or $0.03 per basic and diluted share, compared to a consolidated net loss of $5,025,000 or $0.03 per basic and diluted share for the same prior year period. The increased net loss primarily reflects increased investments in research and development as the company advanced its clinical programs for bavituximab and Cotara(R).

Total revenues for the current quarter increased to $1,675,000 compared to $363,000 for the comparable quarter last year, and were primarily generated from services provided by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

Total costs and expenses increased to $8,077,000 in the third quarter of FY 2008 from $5,643,000 in the same prior year quarter. The increase was primarily related to the increase in the cost of contract manufacturing of $1,066,000 during the quarter resulting from higher reported revenues from external customers, in addition to the increase in research and development expenses of $1,034,000 associated with the advancement of the company's clinical and preclinical product candidates. Research and development expenses were $4,941,000 in the third quarter of FY 2008, compared to $3,907,000 in the third quarter of FY 2007
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
(Date:7/23/2014)... Cord Blood Corporation (NYSE: CO ) ("CCBC" or the ... collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage ... to the mother and child segment, today announced that the two ... Singapore , Hong Kong , ... the Philippines and Malaysia to ...
(Date:7/23/2014)... July 23, 2014 Astra ... and comprehensive consultancy and pharma training services, and ... Safety (ACRES) , a non-profit integrating the expertise ... and maintain a global system for clinical trials, ... to improve the expertise of industry professionals through ...
(Date:7/22/2014)... a solution of rod-shaped metal nanoparticles in water with ... tiny drill bits. Why? No one yet knows exactly. ... Technology (NIST) have clocked their speedand it,s fast. At ... 10 times faster than any nanoscale object submerged in ... rate has opened up the possibility that they could ...
Breaking Biology Technology:BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2
... RIDGE, Tenn., Nov. 29, 2007 -- A water repellent ... Ridge National Laboratory outperforms nature at its best and ... super-water repellent (superhydrophobic) material, developed by John Simpson, is ... patent-pending process could lead to the creation of a ...
... CAMBRIDGE, Mass., Nov. 29 Merrimack Pharmaceuticals,Inc., a ... and,development of novel treatments for autoimmune disease and ... PhD from its Board of,Directors and the addition ... as a Director at Merrimack since May 2006. ...
... GRAND RAPIDS, Mich., Nov. 29 The Center ... the first member of the Xceed,Molecular (http://www.xceedmolecular.com ... role, CMM is the first US site to ... analysis, giving researchers an,important new tool in disease ...
Cached Biology Technology:ORNL super water repellent could cause big wave in market 2Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors 2Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors 3Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community 2
(Date:7/23/2014)... tapeworms, hookworms and a protist called Blastocystis can ... that argues we should rethink our views of organisms that ... paper co-author Julius Luke even ingested three developmental stages of ... After more than a year with the tapeworms, which might ... by now, he says he feels fine. , "I knew ...
(Date:7/23/2014)... and rosemary are packed with healthful compounds, and now ... same way as prescription anti-diabetic medication, scientists report. In ... Agricultural and Food Chemistry , they found that how ... also identified which compounds contribute the most to this ... point out that in 2012, type-2 diabetes affected more ...
(Date:7/23/2014)... preconditioning has been confirmed by many studies, but ... released in the Neural Regeneration Research ... and co-workers from Tongji Hospital Affiliated to Tongji ... China performed cerebral ischemic preconditioning in rats by ... mechanism underlying the neuroprotective effect of ischemic preconditioning. ...
Breaking Biology News(10 mins):Intestinal parasites are 'old friends,' researchers argue 2Intestinal parasites are 'old friends,' researchers argue 3
... 2014   BioNano Genomics announced today the purchase of an ... projects, in completing the genome assembly of Aegilops tauschii, ... researchers at UC Davis, led by Dr. Jan Dvorak , ... the sequence, location, and orientation of all genes and transposable elements ...
... the genome might be important contributors to type 2 diabetes ... don,t encode proteins were once dismissed as "junk DNA", but ... controlling which genes are switched on. The new study, ... first to show how such regions, called regulatory elements, can ...
... Almost one in 10 people will someday experience a kidney ... pain imaginable. This increasingly common condition leads to hundreds of ... A new device developed at the University of Washington would ... body and help them pass by natural means. "Ultrasound ...
Cached Biology News:UC Davis Purchases Irys System From BioNano Genomics To Advance Genome Mapping And Assembly Of Wheat Relative 2UC Davis Purchases Irys System From BioNano Genomics To Advance Genome Mapping And Assembly Of Wheat Relative 3UC Davis Purchases Irys System From BioNano Genomics To Advance Genome Mapping And Assembly Of Wheat Relative 4UC Davis Purchases Irys System From BioNano Genomics To Advance Genome Mapping And Assembly Of Wheat Relative 5Non-coding DNA implicated in type 2 diabetes 2Trial to test using ultrasound to move kidney stones 2Trial to test using ultrasound to move kidney stones 3
... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
TNR-R2...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: